10x Genomics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Outlook for 2024

Gross margin was 63% for the fourth quarter of 2023, as compared to 76% for the corresponding prior year period. The decrease in gross margin was primarily due to product mix with a higher mix of Spatial instruments sold.

Operating expenses were $171.0 million for the fourth quarter of 2023, a 20% increase from $142.5 million for the corresponding prior year period. The increase was primarily driven by $19.6 million of in-process research and development expense related to an agreement to acquire certain intangible and other assets earlier this year and impairment charges related to long-lived assets.

Operating loss was $55.2 million for the fourth quarter of 2023, as compared to an operating loss of $23.1 million for the corresponding prior year period. Operating loss also includes $38.9 million of stock-based compensation for the fourth quarter of 2023, as compared to $41.0 million for the fourth quarter of 2022.

Net loss was $49.0 million for the fourth quarter of 2023, as compared to a net loss of $17.2 million for the corresponding prior year period. This includes $19.6 million of in-process research and development expense related to an agreement to acquire certain intangible and other assets earlier this year.

Full Year 2023 Financial Results

Revenue was $618.7 million for the year ended December 31, 2023, a 20% increase from $516.4 million for 2022.

Gross margin was 66% for full year 2023, as compared to 77% for 2022. The decrease in gross margin was primarily due to product mix with a higher mix of Spatial instruments sold.

Operating expenses were $674.6 million for full year 2023, as compared to $564.0 million for 2022, an increase of 20%. The increase was primarily driven by $61.0 million of in-process research and development expense related to an agreement to acquire certain intangible and other assets earlier this year and higher personnel expenses including stock-based compensation expense.

Operating loss was $265.3 million for full year 2023, as compared to an operating loss of $167.9 million for 2022. This includes $167.0 million of stock-based compensation for full year 2023, as compared to $136.8 million for full year 2022.

Net loss was $255.1 million for full year 2023, as compared to a net loss of $166.0 million for 2022. This includes $61.0 million of in-process research and development expense related to an agreement to acquire certain intangible and other assets earlier this year.

Cash and cash equivalents and marketable securities were $388.7 million as of December 31, 2023.

2024 Financial Guidance 

10x Genomics expects full year 2024 revenue to be in the range of $670 million to $690 million, representing 8% to 12% growth over full year 2023 revenue.

Webcast and Conference Call Information

10x Genomics will host a conference call to discuss the fourth quarter and full year 2023 financial results, business developments and outlook after market close on Thursday, February 15, 2024 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. A webcast of the conference call can be accessed at http://investors.10xgenomics.com. The webcast will be archived and available for replay for at least 45 days after the event.

About 10x Genomics

10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter).

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s product momentum, potential, progress and launches, our expected performance advantages and benefits of using our products and services, customer usage and adoption of our products and our financial performance and results of operations, including our expectations regarding revenue and guidance. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-K and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time.

Disclosure Information

10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.

Contacts

Investors: investors@10xgenomics.com

Media: media@10xgenomics.com

10x Genomics, Inc. Consolidated Statement of Operations (Unaudited) (In thousands, except share and per share data)
	Three Months Ended December 31,				Year Ended December 31,
	2023		2022		2023		2022
Revenue (1)	$         183,979		$         156,232		$         618,727		$         516,409
Cost of revenue (2)	68,197		36,827		209,414		120,386
Gross profit	115,782		119,405		409,313		396,023
Operating expenses:
Research and development (2)	65,267		63,614		270,332		265,667
In-process research and development	19,578		—		60,980		—
Selling, general and administrative (2)	86,125		78,887		343,330		298,300
Total operating expenses	170,970		142,501		674,642		563,967
Loss from operations	(55,188)		(23,096)		(265,329)		(167,944)
Other income (expense):
Interest income	4,637		2,815		16,906		6,647
Interest expense	(8)		(125)		(33)		(476)
Other income (expense), net	3,961		3,995		(307)		(198) Werbung Mehr Nachrichten zur 10x Genomics Inc. Aktie kostenlos abonnieren E-Mail-Adresse Bitte überprüfe deine die E-Mail-Adresse. Benachrichtigungen von ARIVA.DE (Mit der Bestellung akzeptierst du die Datenschutzhinweise) -1 Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink. Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte. Andere Nutzer interessierten sich auch für folgende News 29.05.24 - PR Newswire Rightmove Plc - Directorate Change 29.05.24 - PR Newswire Datang Intnl Pwr Gen - Connected Transaction Announcement 29.05.24 - PR Newswire Datang Intnl Pwr Gen - Announcement on Provision for Asset Impairment $logger->warn("fertig.m SKIPPED - kein Cookie"); # voruebergehend warn, nach Analyse auf Debug setzen